Soluble E-selectin in cancer patients as a marker of the therapeutic efficacy of CM101, a tumor-inhibiting anti-neovascularizaton agent, evaluated in phase I clinical trial

Journal of Cancer Research and Clinical Oncology

Volumn 123, Issue 3, 1997, Pages 173-179

  Wamil, Barbara D ^a   Thurman, Gary B ^a   Sundell, Hakan W ^b   DeVore, Russell F ^b   Wakefield, Gail ^b   Johnson, David H ^b   Wang, Yue Fen ^a   Hellerqvist, Carl G ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY   (United States)

Author keywords

angiogenesis; cancer; CM101; GBS toxin; inflammation; neovascularization

Indexed keywords

ANGIOGENESIS INHIBITOR; CM 101; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; ANGIOGENESIS; ARTICLE; BLOOD LEVEL; CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; INFLAMMATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL;

ADULT; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; E-SELECTIN; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; POLYSACCHARIDES, BACTERIAL; TUMOR MARKERS, BIOLOGICAL;

EID: 0030986163     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004320050046     Document Type: Article

References (29)

1. Banks RE, Gearing AJH, Hemingway IK, Norfolk DR, Perren TJ, Selby PJ (1993) Circulating intercellular adhesion molecule-1 (ICAM-1), E-Seleclin and vascular cell adhesion molecule-1 (VCAM-1) in human malignancies. Br J Cancer 68:122-124
2. Bevilacqua MP, Nelson RM (1993) Selectins. J Clin Invest 91:379-387
3. DeVore R, Johnson DR, Hellerqvist C, Wakefield G, Browning P, Page D, Sundell H, Johnson DH (1995) A phase I study of the anti-neovascularization drug CM101. Proc Am Soc Clin Oncol Annu Meet 14:487
4. Gearing AJH, Newman W (1993) Circulating adhesion molecules in disease. Immunol Today 14:506-512
5. Hakomori S (1994) Novel endothelial cell activation factor(s) released from activated platelets which induce E-selectin expression and tumor cell adhesion to endothelial cells: a preliminary note. Biochem Biophys Res Commun 203:1605-1613
6. Hellerqvist CG (1991) Therapeutic agent and method of inhibiting vascularization of tumors. US Patent 5010062, 23 April 1991. Patents have been issued in Europe, Canada, Australia and Japan
7. Hellerqvist CG, Rojas J, Green RS, Sell S, Sundell H, Stahlman MT (1981) Studies on group B β-hemolytic streptococcus. I. Isolation and partial characterization of an extra-cellular toxin. Pediatr Res 15:892-898
8. Hellerqvist CG, Thurman GB, Page DL, Wang Y-F, Russell BA, Montgomery CA, Sundell HW (1993) Anti-tumor effects of GBS toxin: a polysaccharide exotoxin from group B β-hemolytic streptococcus. J Cancer Res Clin Oncol 120:63-70
9. Hellerqvist CG, DeVore RF, Sundell HW, Thurman GB, Wamil BD, Wakefield GB, Johnson DH (1994) Preliminary results of a phase I trial of CM101 in cancer patients. J Leukoc Biol [Supp] 112:35
10. Hellerqvist C, DeVore R, Thurman G, Wamil B, Zhang M, Wakefield G, Sundell H, Carter C, Van H, Johnson D (1995a) Cytokine production in cancer patients receiving the anti-neovascularization drug CM101. Proc Am Soc Clin Oncol Annu Meet 14:488
11. Hellerqvist CG, DeVore RF, Sundell HW, Thurman GB, Wamil BD, Page DL, Wakefield, GB, Johnson DH (1995b) Early results of a phase I trial of CM101 in cancer patients. Proc Am Assoc Cancer Res Ann Meet 36:224
12. Hellerqvist CG, Van H-P, Carter CE, Liu L, Wamil BD, Page DL, Thurman GB, Sundell HW (1996) CM101 induces a complement-activated inflammatory response targeting tumor neovasculature. Proc Am Assoc Cancer Res Ann Meet 37:487
13. Hollander M, Wolfe DA (1973) The dichotomous data problem. In: RA Bradley, JS Hunter, DG Kendall and GS Watson (Eds) Nonparametric statistical Methods. John Wiley and Sons, New York, 15-25
14. Mackay CR, Imhof BA (1993) Cell adhesion in the immune system. Immunol Today 14:99-102
15. Meekins JW, McLaughlin PJ, West DC, McFadyen IR, Johnson PM (1994) Endothelial cell activation by tumour necrosis factor-alpha (TNF-alpha) and the development of pre-eclampsia. Clin Exp Immunol 98:110-114
16. Newman W, Beall LD, Carson CW, Hunder GG, Graben N, Randhawa ZI, Gopal TV, Wiener-Kronish J, Matthay MA (1993) Soluble E-selectin is found in supernatant of activated endothelial cells and is elevated in the serum of patients with septic shock. J Immunol 150:644-654
17. Nguyen M, Watanabe H, Budson AE, Richie JP, Hayes DF, Folkman J (1994) Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancer. J Natl Cancer Inst 86:356-361
18. Rojas J, Green RS, Hellerqvist CG, Olegard R, Brigham KL, Stahlman MT (1981) Studies on group B β-hemolytic streptococcus. II. Effects on pulmonary hemodynamics and vascular permeability in unanesthetized sheep. Pediatr Res 15:899-904
19. Rojas J, Larson LE, Hellerqvist CG, Brigham KL, Gray ME, Stahlman MT (1983) Pulmonary hemodynamic and ultra-structural changes associated with group B streptococcal toxemia in adult sheep and newborn lambs. Pediatr Res 17:1002-1008
20. Sawada R, Tsuboi S, Fukuda M (1994) Differential E-selectin-dependent adhesion efficiency in sublines of a human colon cancer exhibiting distinct metastatic potentials. J Biol Chem 269:1425-1431
21. Sciacca FL, Stürzl M, Bussolino F, Sironi M, Brandstetter H, Zietz C, Zhou D, Matteucci C, Peri G, Sozzani S, Benelli R, Arese M, Albini A, Cololta F, Mantovani A (1994) Expression of adhesion molecules, platelet-activating factor, and chemokines by Kaposi's sarcoma cells. J Immunol 153:4816
22. Sundell HW, Fish WG, Sandberg KL, Edberg KE, Pappas RS, Hellerqvist CG (1990) Lung injury by streptococcal toxins. In: Brigham L, Stahlman MT (eds) Respiratory distress syndromes. Vanderbilt University Press, Nashville, Tenn, pp 58-70
23. Sundell HW, Yan H-P, Wu K, Wamil BD, Gaddipati R, Carter CE, Stahlman MT, Hellerqvist CG (1996) Isolation and identification of group B β-hemolytic streptococcal (GBS) toxin from septic newborn infants. Pediatr Res 39:302A
24. Thurman GB, Russell BA, York GE, Wang Y-F, Page DL, Sundell HW, Hellerqvist CG (1994a) Effects of GBS toxin on long-term survival of mice bearing transplanted Madison lung Tumors. J Cancer Res Clin Oncol 120:479-484
25. Thurman GB, Wamil BD, Yan H, Zhang M, Johnson DH, DeVore RF, Wakefield GB, Hellerqvist CG (1994b) Cytokine production in cancer patients in response to CM101, a polysaccharide exotoxin from group B streptococcus (GBS). J Leukoc Biol [Suppl] 113:36
26. Thurman GB, Page DL, Wamil BD, Wilkinson LE, Kasami M, Hellerqvist CG (1996) Acute inflammatory changes in subcutaneous microtumors in the ears of mice induced by intravenous CM101 (GBS toxin). J Cancer Res Clin Oncol 122:549-553
27. Wamil BD, Price JO, Minton PA, Sundell HW, Thurman GB, Van H-P, Carter CE, Hellerqvist CG (1996) Leukocyte activation in response to CM101 treatment of cancer patients. Proc Am Assoc Cancer Res Annu Meet 37:487
28. Warren JS (1993) Cellular processes such as leukocyte activation, chemotaxis, intercellular adhesion and secretion of proinflammatory soluble mediators are regulated by a complex set of cell surface, matrix-associated and soluble mediators. Drug News Perspect 6:450-459
29. Whitley MZ, Thanos D, Read MA, Maniatis T, Collins T (1994) A striking similarity in the organization of the E-selectin and beta interferon gene promoters. Mol Cell Biol 14:6464-6475